Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-2.14bn
- Incorporated2016
- Employees37.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Human Metabolome Technologies Inc | 1.35bn | 243.25m | 3.56bn | 58.00 | 14.64 | 1.83 | 10.81 | 2.65 | 41.12 | 41.12 | 227.58 | 329.08 | 0.5499 | 15.07 | 7.52 | 23,201,220.00 | 9.94 | 8.49 | 12.91 | 10.80 | 64.60 | 69.25 | 18.08 | 13.21 | 3.25 | -- | 0.1041 | 18.31 | 3.57 | -- | -14.88 | -- | -- | -- |
BrightPath Biotherapeutics Co Ltd | 84.00k | -1.20bn | 4.11bn | 24.00 | -- | 5.19 | -- | 48,878.26 | -18.25 | -18.25 | 0.0013 | 9.44 | 0.00008 | -- | 3.50 | 3,500.00 | -108.84 | -51.56 | -116.51 | -54.32 | 75.00 | 68.63 | -1,431,842.00 | -22,321.82 | -- | -274.19 | 0.00 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
FunPep Co Ltd | 530.00k | -727.29m | 4.41bn | 15.00 | -- | 1.65 | -- | 8,316.22 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
Cyfuse Biomedical KK | 60.88m | -671.82m | 4.71bn | 21.00 | -- | 1.61 | -- | 77.34 | -84.88 | -84.88 | 7.71 | 360.49 | 0.0148 | 0.5613 | 24.17 | 2,899,143.00 | -16.32 | -- | -19.11 | -- | 58.30 | -- | -1,103.48 | -- | 6.02 | -84.25 | 0.2153 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
Kidswell Bio Corp | 2.87bn | -1.13bn | 4.80bn | 42.00 | -- | 6.51 | -- | 1.67 | -30.62 | -30.62 | 77.19 | 18.12 | 0.7495 | 1.37 | 7.46 | 68,290,810.00 | -29.48 | -57.41 | -47.94 | -81.13 | 42.46 | 55.20 | -39.33 | -123.52 | 1.45 | -22.17 | 0.7709 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
DNA Chip Research Inc | 629.13m | -172.44m | 4.97bn | 37.00 | -- | 6.98 | -- | 7.91 | -26.95 | -26.95 | 97.41 | 105.25 | 0.739 | 9.29 | 5.94 | 17,003,490.00 | -20.25 | -23.49 | -24.51 | -26.70 | 28.19 | 14.28 | -27.41 | -54.10 | 2.98 | -926.97 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
Kringle Pharma Inc | 79.22m | -793.94m | 5.97bn | 13.00 | -- | 2.55 | -- | 75.38 | -134.08 | -134.08 | 13.09 | 344.17 | 0.0274 | -- | 1.66 | 6,093,462.00 | -27.49 | -19.00 | -29.10 | -20.23 | -- | -- | -1,002.26 | -156.51 | 30.96 | -- | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
Carna Biosciences, Inc. | 1.44bn | -1.36bn | 6.27bn | 67.00 | -- | 1.95 | -- | 4.35 | -78.70 | -78.70 | 83.68 | 178.16 | 0.3493 | 1.22 | 9.81 | 21,506,880.00 | -33.00 | -14.45 | -36.04 | -16.95 | 87.84 | 90.59 | -94.48 | -35.42 | 9.17 | -- | 0.0268 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
Chiome Bioscience Inc | 587.30m | -1.12bn | 6.37bn | 51.00 | -- | 5.48 | -- | 10.85 | -21.19 | -21.19 | 11.09 | 18.99 | 0.3622 | 4.68 | 7.96 | 11,515,750.00 | -69.09 | -50.50 | -96.39 | -57.38 | 55.28 | 57.53 | -190.76 | -224.74 | 3.17 | -816.71 | 0.2144 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
Modalis Therapeutics Corp | 0.00 | -2.14bn | 6.98bn | 37.00 | -- | 3.97 | -- | -- | -64.28 | -64.28 | 0.00 | 28.21 | 0.00 | -- | -- | 0.00 | -100.32 | -29.19 | -110.17 | -30.02 | -- | -- | -- | -597.35 | 12.87 | -- | 0.1274 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
Veritas In Silico Inc | -100.00bn | -100.00bn | 7.38bn | 15.00 | -- | 3.13 | -- | -- | -- | -- | -- | 363.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 63.22 | -- | 0.00 | -- | 101.54 | -- | 123.38 | -- | -- | -- |
TMS Co Ltd | 0.00 | -1.06bn | 7.58bn | 14.00 | -- | 2.36 | -- | -- | -27.96 | -27.96 | 0.00 | 79.72 | 0.00 | -- | -- | 0.00 | -30.42 | -- | -31.24 | -- | -- | -- | -- | -- | 29.35 | -1,052.64 | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
Noile-Immune Biotech Inc | 308.06m | -979.88m | 7.92bn | 28.00 | -- | 1.58 | -- | 25.72 | -22.63 | -22.63 | 7.11 | 115.62 | 0.0549 | 0.0625 | 6.35 | 11,002,180.00 | -17.47 | -- | -17.90 | -- | 99.80 | -- | -318.08 | -- | 66.40 | -- | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
Linical Co Ltd | 12.15bn | 252.44m | 9.65bn | 662.00 | 34.89 | 1.08 | 12.25 | 0.794 | 11.18 | 11.18 | 538.03 | 362.32 | 0.6633 | -- | 3.45 | 18,356,870.00 | 1.38 | 4.01 | 2.37 | 6.33 | 29.26 | 30.99 | 2.08 | 5.48 | -- | -- | 0.2518 | 50.81 | -1.67 | 1.70 | -66.32 | -9.86 | -10.18 | 4.56 |
OncoTherapy Science, Inc. | 562.70m | -1.19bn | 10.05bn | 54.00 | -- | 13.24 | -- | 17.86 | -5.39 | -5.39 | 2.55 | 2.80 | 0.4431 | 5.18 | 15.94 | 10,420,280.00 | -93.70 | -55.67 | -129.70 | -63.82 | -30.63 | -1.49 | -211.47 | -247.47 | 2.67 | -255.18 | 0.1146 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
Holder | Shares | % Held |
---|---|---|
Evolution Capital Management LLCas of 11 Jul 2024 | 5.85m | 15.05% |
Nikko Asset Management Co., Ltd.as of 20 Apr 2023 | 1.42m | 3.65% |
Rheos Capital Works, Inc. (Investment Management)as of 25 Apr 2023 | 1.40m | 3.59% |
Chibagin Asset Management Co. Ltd.as of 30 May 2023 | 0.00 | 0.00% |
Amundi Japan Ltd.as of 12 Sep 2022 | 0.00 | 0.00% |
Daiwa Asset Management Co. Ltd.as of 29 Aug 2022 | 0.00 | 0.00% |
Asset Management One Co., Ltd.as of 16 Sep 2022 | 0.00 | 0.00% |
FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
JPMorgan Asset Management (Japan) Ltd.as of 25 Apr 2023 | 0.00 | 0.00% |
SPARX Asset Management Co., Ltd.as of 17 Oct 2022 | 0.00 | 0.00% |